Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 17/20 | 0.50 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.49 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312715 | 0.89 | MALT1 (0.60) | MALT1SLC9A1SLC9A2OPRM1OPRD1 | |
| SCHEMBL6313463 | 0.87 | SLC9A1 (0.53) | MALT1SLC9A1SLC9A2OPRM1OPRD1 | |
| SCHEMBL6313388 | 0.84 | SLC9A1 (0.53) | MALT1SLC9A1SLC9A2OPRM1OPRD1 | |
| SCHEMBL4455784 | 0.84 | MALT1 (0.53) | MALT1SLC9A1SLC9A2OPRM1OPRD1 | |
| SCHEMBL3716453 | 0.83 | SLC9A1 (0.70) | MALT1SLC9A1SLC9A2OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL6319934 | 0.83 | MALT1 (0.52) | MALT1SLC9A1SLC9A2OPRM1OPRD1 | |
| SCHEMBL6312521 | 0.83 | SLC9A1 (0.54) | MALT1SLC9A1SLC9A2OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL6319943 | 0.82 | SLC9A1 (0.69) | MALT1SLC9A1SLC9A2OPRM1OPRD1 | |
| SCHEMBL20265829 | 0.80 | MALT1 (0.57) | MALT1SLC9A1SLC9A2OPRM1OPRD1 | |
| SCHEMBL6318233 | 0.78 | MALT1 (0.61) | MALT1SLC9A1SLC9A2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1454902-A1 | N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | MALT1 4089/4885SLC9A1 5/4885SLC9A2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.